This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookies Policy.

Banner Tittle 1 Banner Tittle 2 Banner Tittle 3



Based on the abstracts received and accepted for oral presentation, general sessions will be devoted to either specific subtypes of lymphoid neoplasia (e.g. mantle cell lymphomas, follicular lymphomas, T-cell lymphomas, etc), or to the presentation of laboratory and clinical research data grouped around a biologic topic (for example, microenvironment, signalling pathway, surface antigens).


"Focus on..." are parallel oral sessions highlighting abstracts of scientific value but not selected for oral presentation during the general sessions. These sessions will be run in parallel and each will be focused on a particular topic. The one-hour sessions will consist of six presentations of 10 minutes each, including discussion.


Key Note Lectures:

- Henry Kaplan Memorial Lecture and San Salvatore Foundation Award 

Title to be announced
Carl H. June, Philadelphia, PA (USA)

- Gianni Bonadonna Memorial Lecture (supported by American Association for Cancer Research)

“Precision Epigenetic Therapy for B-cell lymphomas”

Ari M. Melnick, New York, NY (USA)

- John Ultmann Memorial Lecture (supported by European School of Oncology)

“Thirty years of T-cell lymphomas”
Philippe Gaulard, Créteil (France)


Educational symposia (parallel sessions):


a) "Treating Hodgkin Lymphoma in the new millennium

New first lines: Peter W.M. Johnson, Southampton (UK)

Relapsing/Refractory: Ann S. LaCasce, Boston, MA (USA)

Elderly patients: Andreas Engert, Cologne (Germany) - Chairman


b) “New drugs for NHL: beyond chemotherapy

Immunotherapies: Renier J. Brentjens, New York, NY (USA)

New drugs for old targets: Gilles A. Salles, Lyon (France) - Chairman

New drugs for new targets: Anas Younes, New York, NY (USA)


Meet the Professor sessions: 

1) Multiple myeloma: every year a new standard? - S. Vincent Rajkumar, Rochester, MN (USA)

2) How to approach CLL in clinical practice - Michael Hallek, Cologne (Germany)

3) Managing the toxicities of CAR T-cell therapy - Sattva S. Neelapu, Houston, TX (USA)

4) What we should know about NK/T-cell lymphomas – Weili Zhao, Shanghai (China)

5) Cutaneous lymphomas – Werner Kempf, Zurich (Switzerland)

6) PCNSL, a curable disease – Tracy T. Batchelor, Boston, MA (USA)

7) Breast implant associated ALCL and other rare T-cell lymphomas – Laurence de Leval, Lausanne (CH)

8) Liquid biopsy:  a clinical tool, already? - Wyndham H. Wilson, Bethesda, MD (USA)

9) Double Hit lymphoma, so what? - Andrew Davies, Southampton (UK)

10) The modern approach to mantle cell lymphoma – Simon Rule, Plymouth (UK)

11) Hairy Cell leukemia, new treatment options - Brunangelo Falini, Perugia (Italy)

12) Rare B cell lymphomas in children and adolescents – Wilhelm Wössmann, Hamburg (Germany) and Leticia Quintanilla-Martinez de Fend, Tübingen (Germany)


Clinical discussion sessions have presenters of outstanding centers addressing cases which are not trivial nor very rare, but rather situations commonly encountered where the solution remains controversial. The format is a sort of Europe vs. USA debate: we had Lysa (France) vs Mayo Clinic in 2013, FIL (Italy) vs New York centers in 2015 and German vs Californian institutes in 2017.

In 2019 we will have the following Spanish vs Texan experts presenting cases and discussing the treatment options:

1) HL: Ana Maria Sureda Balari vs Hun Ju Lee

2) FL/Indolent Lymphoma: Mariano Provencio Pulla vs Loretta J. Nastoupil

3) PTCL: Alejandro Martín vs Nathan H. Fowler

4) DLBCL: Eva Giné Soca vs Jason R. Westin

5) CLL: Julio Delgado vs Philip A. Thompson
6) Clinico-pathological difficult cases: Armando Lopez-Guillermo vs Fredrick B. Hagemeister

7) Radiotherapy in lymphoma: Timothy Illidge (Manchester, UK) vs Bouthaina S. Dabaja



Ongoing trials presentation: this session will comprise abstracts describing trials in progress. Conditions for being selected for presentation at this session are:
- already started enrolment, 

- still possible accrual of new patients.
The session should not be regarded as an advertisement for new drugs. Trials which are close to completion (i.e. not available for other possible participants) and closed trials will not be considered for presentation.


15-ICML Highlights

“Take home messages” 

Speaker to be announced


Special AACR-ICML session

After the 2015 and 2017 positive and fruitful experiences, AACR and ICML will organize once again in 2019 a special joint session. The session will be devoted to the role of pre-clinical models as bridges to early clinical phases.


Special sessions devoted to radiotherapy, organized in collaboration with ILROG (International Lymphoma Radiation Oncology Group): two satellite workshops open to all 15-ICML attendees will take place.
Details will be available closer to the event at 


IBSA Foundation for Scientific Research - Special Forum

As in 2017, when the event "Basic mechanisms of cancer immunotherapy” took place, ICML participants will again have the possibility to join the IBSA Foundation Special Forum. The forum will be organised in the Lugano University Auditorium and the program will be defined in collaboration with the Foundation for the Institute of Oncology Research (IOR).


IV International Workshop on Canine Lymphoma

This well-attended meeting fosters interdisciplinary contacts between researchers studying lymphoma in canine and other species. The 2019 edition will comprise an invited plenary lecture on a cutting-edge topic, an update on the activities of the European Canine Lymphoma Network, a round table on state-of-the-art on canine multicentric lymphoma staging, and, for the first time, a session with free oral research presentations.


The provisional Program at a Glance can be downloaded here.

Please note that this draft program has been updated on May 2018. The final program will differ in some details. In particular, the content of the general sessions and “Focus on…” sessions will be defined on the basis of the abstract evaluation.